Related Experiment Video
Updated: Jan 29, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With
Laurissa Ouaguia1,2, Vincent Leroy3,4,5, Tania Dufeu-Duchesne1,4
1Institute for Advanced Biosciences, Immunobiology and Immunotherapy in Chronic Diseases, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes, Grenoble, France.
Insights
Chronic hepatitis B virus (HBV) infection impairs dendritic cells (DCs), crucial immune sentinels. This study reveals HBV hijacks the immune system by subverting DCs, offering new therapeutic targets for immune control.
Area of Science:
- Immunology
- Hepatology
- Virology
Background:
- Chronic hepatitis B virus (HBV) infection poses a significant health burden, potentially leading to cirrhosis and hepatocellular carcinoma.
- Understanding HBV's immune evasion mechanisms is crucial, as viral pathogenesis is closely linked to host immunity.
- Dendritic cells (DCs) are key orchestrators of antiviral immunity, but their role in HBV pathogenesis requires further exploration.
Purpose of the Study:
- To investigate the phenotypic and functional characteristics of circulating and intrahepatic dendritic cell subsets in chronic HBV infection.
- To elucidate the mechanisms by which HBV evades immune surveillance through DC subversion.
- To identify potential therapeutic strategies for restoring immune control in chronic HBV infection.
Main Methods:
- Multi-parametric flow cytometry was employed to analyze BDCA1+ cDC2, BDCA2+ pDCs, and BDCA3+ cDC1 subsets in blood and liver biopsies.
- Study included 130 chronically HBV-infected patients and 85 healthy donors for blood collection.
- Liver biopsies were obtained from 29 chronically HBV-infected patients and 33 non-viral infected patients.
Main Results:
- Significant modulations in the frequencies and activation status of blood and liver DCs were observed in chronic HBV patients.
- Impaired expression of immune checkpoints and TLR molecules on circulating DC subsets was noted.
- Circulating and hepatic pDCs and cDCs showed impaired maturation upon TLR agonist stimulation, with reduced production of key cytokines (IL-12p70, TNFα, IFNα, IFNλ1, IFNλ2) in circulating DCs, while intrahepatic DCs remained functional. These changes correlated with HBsAg and HBV DNA levels.
Conclusions:
- Chronic HBV infection profoundly alters the distribution, phenotype, and function of all blood DC subsets, alongside modulations in intrahepatic DCs.
- HBV actively subverts DCs, representing a novel mechanism of viral immune evasion.
- These findings provide critical insights into HBV immunopathogenesis and offer a basis for developing novel therapeutic strategies targeting immune control.
Abstract:
Background and aims: Chronic hepatitis B virus (HBV) infection is a major health burden potentially evolving toward cirrhosis and hepatocellular carcinoma. HBV physiopathology is strongly related to the host immunity, yet the mechanisms of viral evasion from immune-surveillance are still misunderstood. The immune response elicited at early stages of viral infection is believed to be important for subsequent disease outcome. Dendritic cells (DCs) are crucial immune sentinels which orchestrate antiviral immunity, which offer opportunity to pathogens to subvert them to escape immunity. Despite the pivotal role of DCs in orientating antiviral responses and determining the outcome of infection, their precise involvement in HBV pathogenesis is not fully explored. Methods: One hundred thirty chronically HBV infected patients and 85 healthy donors were enrolled in the study for blood collection, together with 29 chronically HBV infected patients and 33 non-viral infected patients that were included for liver biopsy collection. In a pioneer way, we investigated the phenotypic and functional features of both circulating and intrahepatic BDCA1+ cDC2, BDCA2+ pDCs, and BDCA3+ cDC1 simultaneously in patients with chronic HBV infection by designing a unique multi-parametric flow cytometry approach. Results: We showed modulations of the frequencies and basal activation status of blood and liver DCs associated with impaired expressions of specific immune checkpoints and TLR molecules on circulating DC subsets. Furthermore, we highlighted an impaired maturation of circulating and hepatic pDCs and cDCs following stimulation with specific TLR agonists in chronic HBV patients, associated with drastic dysfunctions in the capacity of circulating DC subsets to produce IL-12p70, TNFα, IFNα, IFNλ1, and IFNλ2 while intrahepatic DCs remained fully functional. Most of these modulations correlated with HBsAg and HBV DNA levels. Conclusion: We highlight potent alterations in the distribution, phenotype and function of all DC subsets in blood together with modulations of intrahepatic DCs, revealing that HBV may hijack the immune system by subverting DCs. Our findings provide innovative insights into the immuno-pathogenesis of HBV and the mechanisms of virus escape from immune control. Such understanding is promising for developing new therapeutic strategies restoring an efficient immune control of the virus.
Related Concept Videos
Neurons: The Cell Body and the Dendrites
Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
Fetal Circulation
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
iPS Cell Differentiation
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

